Cerenome Secures $20M 3i Financing Facility
Analysis based on 6 articles · First reported Sep 10, 2026 · Last updated Sep 13, 2026
The financing removes near-term liquidity concerns for Cerenome by extending its cash runway into 2028, which is likely to be viewed positively by holders of the thinly traded CNSY stock. The royalty-based, minimally dilutive structure limits shareholder dilution, though the small deal size means broader market impact is negligible.
Cerenome, Inc. (Nasdaq: CNSY), a clinical-stage CNS oncology company, announced on September 10, 2026 that it entered into a financing agreement with 3i, LP for a senior secured facility of up to $20 million with royalty-based repayments. The company received an initial tranche of funding at closing, with future tranches available upon achieving certain milestones. The financing is intended to support the commercial scale-up of Cerenome's proprietary laboratory-developed tests, particularly its CNSide cerebrospinal fluid assay platform, and to broaden its therapeutic pipeline. According to CFO Andrew Sims, the facility is designed to be minimally dilutive to stockholders, and the company forecasts its cash runway now extends well into 2028 when combining the 3i facility, other existing facilities, current cash, and projected CNSide-related sales and cash flow. Additional transaction details, including milestone-linked future tranches and royalty obligations to 3i Fund, will be included in a Current Report on Form 8-K filed with the United States — United States Securities and Exchange Commission. Cerenome's platform integrates precision diagnostics, targeted therapeutics, and artificial intelligence, with its lead therapeutic REYOBIQ (rhenium Re186 obisbemeda) in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. CNSide Diagnostics, LLC is a wholly owned subsidiary developing and commercializing the CNSide laboratory-developed tests.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard